Research Title: Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy
Sponsor: Aerpio Therapeutics, LLC
Principal Investigator: Sri Krishna Mukkamala, M.D.
Description: The purpose of this study is to evaluate the safety and efficacy of subcutaneously administered AKB-9778 15mg once daily or 15mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR).
Start Date: August 2017
Project Personnel: Leslie Marcus, CCRC; Caitlin Harrison, COA; Halie Sklanka, CRC
Location(s): Marietta; 833 Campbell Hill Street, Suite 300, Marietta, GA 30060